Streetbeat News

Stock Prices

SPY

The USA ADP Nonfarm Employment Change for September was reported at 143K, surpassing the estimated 124K and the prior month's 103K. This indicates a stronger-than-expected job growth in the private sector.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:15 pm

ESPR

Esperion's European partner, Daiichi Sankyo Europe, reported positive real-world results from the MILOS study in Germany, showing significant LDL-C reduction with bempedoic acid. The study demonstrated a 7-fold increase in patients achieving LDL-C goals, confirming the drug's effectiveness and safety.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:15 pm

BNTX

GOOG

GOOGL

Google DeepMind, part of Alphabet Inc., and BioNTech are collaborating to develop AI lab assistants to enhance scientific research. This partnership aims to revolutionize research by using AI to facilitate interdisciplinary collaboration and automate routine tasks, potentially boosting productivity and aiding in cancer treatment research.

Portfolio Pulse from Benzinga Neuro

October 02, 2024 | 12:11 pm

MGNI

SSTK

The article highlights three oversold stocks in the communication services sector: Magnite Inc (MGNI), Shutterstock Inc (SSTK), and Eventbrite Inc (EB). These stocks have RSI values near or below 30, indicating potential undervaluation. Analyst Laura Martin reiterated a Buy rating for Magnite with a $15 price target. Shutterstock announced a leadership change, and Eventbrite engaged in repurchase transactions for its convertible notes.

Portfolio Pulse from Avi Kapoor

October 02, 2024 | 12:09 pm

URGN

UroGen Pharma has dosed the first patient in a Phase 3 trial for UGN-103, targeting low-grade intermediate-risk non-muscle invasive bladder cancer. The trial features an improved manufacturing and reconstitution process.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:07 pm

ALUR

KXIN

NKE

PIK

QSG

VEEE

In Wednesday's pre-market session, several consumer discretionary stocks experienced significant movements. Kaixin Holdings (KXIN) saw an 80.2% increase, while Nike (NKE) fell by 7.7% following its Q1 earnings report. Other notable gainers include QuantaSing Group (QSG) and Allurion Technologies (ALUR), while Kidpik (PIK) and Twin Vee PowerCats (VEEE) were among the losers.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:06 pm

AUTL

CDIO

CTCX

ERNA

HUM

IGMS

KAPA

MHUA

MODV

SLXN

TIVC

XAIR

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Eterna Therapeutics, ModivCare, Cardio Diagnostics, Autolus Therapeutics, Beyond Air, and Meihua Intl Medical Techs saw notable gains. Conversely, Humana, Carmell, Tivic Health Systems, Kairos Pharma, IGM Biosciences, and Silexion Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

BYND

CJJD

DADA

RLX

Several consumer staples stocks experienced significant movements in Wednesday's pre-market session. Notable gainers include China Jo-Jo Drugstores, RLX Technology, and Dada Nexus, while Lamb Weston Holdings and Beyond Meat were among the losers.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

AKTS

API

MTC

Several information technology stocks experienced significant movements in Wednesday's pre-market session. Agora (API) saw a remarkable increase of 136.4%, while MMTEC (MTC), Kingsoft Cloud Holdings (KC), and others also posted gains. Conversely, Akoustis Technologies (AKTS) and other stocks faced declines.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

PDSB

PDS Biotech announced a 36-month overall survival rate of 84.4% in a Phase 2 trial for locally advanced cervical cancer patients treated with Versamune HPV and chemoradiation. Fully treated patients showed 100% survival and progression-free rates.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:04 pm